Xenon Pharmaceuticals Inc. (XENE) Stock Analysis & Investment Frameworks
Xenon Pharmaceuticals Inc. (XENE) stock analysis on Invetso. Review Xenon Pharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Xenon Pharmaceuticals Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
Xenon Pharmaceuticals Inc. Key Financial Metrics
- Market Cap: $3.48B
- Revenue: $7.50M
- ROE: -43.98%
- ROIC: -35.10%
- Dividend Yield: N/A
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Xenon Pharmaceuticals Inc. Investment Frameworks
Invetso analyzes Xenon Pharmaceuticals Inc. (XENE) across the following frameworks:
- Xenon Pharmaceuticals Inc. 10Y Growth Potential
- Xenon Pharmaceuticals Inc. Scenario Analysis
- Xenon Pharmaceuticals Inc. Risks & Opportunities
- Xenon Pharmaceuticals Inc. Economic Moat
- Xenon Pharmaceuticals Inc. Business Model
- Xenon Pharmaceuticals Inc. Management
- Xenon Pharmaceuticals Inc. SWOT Analysis
- Xenon Pharmaceuticals Inc. Porter's 5 Forces
- Xenon Pharmaceuticals Inc. PESTLE Analysis
- Xenon Pharmaceuticals Inc. ESG Analysis